Case Report Open Access

Journal of Molecular Biomarkers & DiagnosisJo

urna

l of M

olecular Biomarkers &

Diagnosis

ISSN: 2155-9929

El-Sabaawy et al., J Mol Biomark Diagn 2017, 8:4DOI: 10.4172/2155-9929.1000348

Volume 8 • Issue 4 • 1000348J Mol Biomark Diagn, an open access journalISSN:2155-9929

*Corresponding author: Maha Elsabaawy, Department of Hepatology,National Liver Institute, Menoufia University, Egypt, Tel: 020482223216;E-mail: maha.ahmed@liver.menofia.edu.eg

Received May 27, 2017; Accepted June 26, 2017; Published June 28, 2017

Citation: El-Sabaawy MM, Abdel-Sameea E, Abdallah AR, El-Refaey A, Soltan M, et al. (2017) IgG4 Sclerosing Cholangitis and Post Infantile Giant Cell Hepatitis: A Case Report of an Extraordinary Co-presentation. J Mol Biomark Diagn 8: 348. doi: 10.4172/2155-9929.1000348

Copyright: © 2017 El-Sabaawy MM. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

IgG4 Sclerosing Cholangitis and Post Infantile Giant Cell Hepatitis: A Case Report of an Extraordinary Co-presentation Maha M El-Sabaawy1*, Eman Abdel-Sameea1, Ayat R Abdallah2, Ahmed El-Refaey3, Mervat Soltan3 and Nemine Ehsan3

1Department of Hepatology, National Liver Institute, Menoufia University, Egypt2Epidemiology and Preventive Medicine, National Liver Institute, Menoufia University, Egypt3Department of Pathology, National Liver Institute, Menoufia University, Egypt

AbstractBackground: Giant cell hepatitis is rarely described in adults; referred to as post infantile giant cell hepatitis

(PIGCH). Most reports have mentioned PIGCH's association with systemic lupus erythromatosis, autoimmune hepatitis, lymphoma, and leukemia. However, links with other medical disorders are still evolving.

Reports of primary sclerosing cholangitis (PSC) presenting as IgG4-SC has been typically described in association with other IgG4-related disorders, most frequently autoimmune pancreatitis. However, some cases of isolated IgG4-SC have been reported. Herein; we report a case of IgG4-SC presented by PIGCH.

Case description: A 29-year-old gentleman presented with two month jaundice and biochemical evidence of acute hepatitis. He reported no history of drug exposure, had no gall bladder or pancreatic disease, nor prior similar attacks. The work up revealed negative serology for viral hepatitis. Markers of autoimmune liver disease were negative except for pANCA, and serum levels of pancreatic enzymes, copper and ceruplasmin were normal, and urinary copper was normal.

Results: Abdominal sonography and MRCP showed normal pancreas and biliary tract. ERCP showed that the common bile duct had a single short narrowed segment with thickened walls. Histological examination of colonoscopic biopsies taken from the terminal ileum and colon demonstrated no pathological alterations. Liver histology showed evidence of parenchymal extinction with extensive giant cell transformation, ductular proliferation, cholestasis, and positive IgG4 staining, a picture suggestive of PSC and PIGCH.

Discussion: In this case, we did not test for serum levels of IgG4, and resorted to immune-staining of liver tissue, as this is the hallmark for diagnosing IgG4-SC. Histopathological features and, more definitely, the positive IgG4 immunostaining were present in the liver tissue, which were crucial in diagnosing this case as IgG4-SC (IAC).

Conclusion: This case presented with both IgG4-SC and biopsy proven PIGCH, and had a favourable outcome with biliary drainage and immuno-suppression therapy

Keywords: Pancreatobiliary system; Abdominal ultrasound,Cholangiopathy; Immunosuppressive agents; Liver cirrhosis

IntroductionPrimary sclerosing cholangitis (PSC) is characterized by chronic

inflammation of the extrahepatic and/or intrahepatic bile ducts along with obliterative fibrosis and ultimately, liver cirrhosis [1,2]. Multidisciplinary team cooperation is essential for proper diagnosis of PSC (2). Immunoglobulin G4-related disease (IgG4-RD) is a chronic, systemic, multiorgan, inflammatory and sclerosing disease [3]. IgG4 associated sclerosing cholangitis (IgG4-SC) - as a variant of PSC - had been correctly reclassified as IgG4-RD-SC) [4]. Being characterized by a favorable response to glucocorticoids and immunosuppressive agents makes the distinction between IgG4-SC and PBC mandatory [5]. The diagnostic value of IgG4 serum levels is questioned as about 40% of IgG4-RD patients have normal serum levels [4,5]. Interplay between IgG4 positive tissue immunostaining, along with both clinical and cholangiographic features of cholangiopathy, is required for proper diagnosis [5]. Histopathological discrimination between IgG4-SC and cholangiocarcinoma is essential; however, this is not usually easy with the difficulty in the endoscopic transpapillary bile duct biopsy [6].

PIGCH is a histological description with unspecified etiology that clinically presents by disturbed liver function [7]. It represents a rare form of acute liver injury that can progress to fulminant hepatic failure, occasionally even necessitating liver transplantation [8]. The multinucleated giant hepatocytes are the discriminative

histopathological feature of PIGCH [9]. Autoimmunity and infection are the two pathognomonic milestones of PIGCH [10].

Case PresentationA 29-year old male accountant presented to the National Liver

Institute's hospital with two month jaundice associated with itching, nausea and vomiting that have been gradually increasing, with no fever. The patient had no history of prior medical problems. Clinical examination revealed jaundice and a mildly enlarged liver. Laboratory investigations confirmed the diagnosis of acute hepatitis (Table 1, Figures 1 and 2). Abdominal ultrasound and MRCP demonstrated normal images for the gall bladder and pancreatobiliary system. He was negative for hepatitis B surface antigen (HBsAg) anti-hepatitis B core (HBc)-IgG, anti-HBc-IgM, anti-EBV-IgM, anti-CMV-IgM, anti-

Citation: El-Sabaawy MM, Abdel-Sameea E, Abdallah AR, El-Refaey A, Soltan M, et al. (2017) IgG4 Sclerosing Cholangitis and Post Infantile Giant Cell Hepatitis: A Case Report of an Extraordinary Co-presentation. J Mol Biomark Diagn 8: 348. doi: 10.4172/2155-9929.1000348

Page 2 of 5

Volume 8 • Issue 4 • 1000348J Mol Biomark Diagn, an open access journalISSN:2155-9929

HIV-Ab, and anti-HSV-IgM), and polymerase chain reaction (PCR) for HCV-RNA. Serum ferritin and urinary copper were within normal

ranges. Antinuclear antibody (ANA), ant-smooth muscle antibody (ASMA) anti-mitochondrial antibody (AMA) and anti-liver-kidney microsomal antibody (anti-LKM-1) were negative, and perinuclear anti-neutrophil cytoplasmic antigen (p-ANCA) was positive (1/120). Serum levels of alpha-fetoprotein, carcinoembryonic antigen and CA19-9 were within normal ranges.

ResultsHistopathological examination revealed moderately disturbed

lobular architecture by fibrous expansion of the portal tracts exhibiting moderate bile ductular proliferation with accompanying portal tract edema with moderate to marked mixed inflammation (lymphoplasmacytic and neutrophils) exceeding the limiting plates with the numerous IgG4 positively stained plasma cells both in bile ducts and liver tissue. There was moderate bile duct proliferation with marked intracellular and intracanalicular cholestasis. Parenchyma showed lobular disarray with loss of trabecular arrangement of hepatocytes that was totally replaced by giant cell transformation. This picture favored the diagnosis of IgG4-SC with cirrhosis and giant cell hepatitis (Figures 3-7). By the second week, laboratory data showed peaking of liver enzymes both hepatocellular and cholestatic with persistence of hyperbilirubinemia. The patient received antihistaminics and phototherapy for itching. ERCP showed a short segment of thickened CBD (Figure 8) with dilatation of the intrahepatic biliary radicles, further supporting the diagnosis of SC, but warranted exclusion of cholangiocarcinoma. Biopsy from thickened segment of the common bile duct (CBD) was technically unfeasible, and a precut followed by a 10 French plastic stent insertion were done. Colonoscopy was normal and histopathological examination of biopsies taken from the colon and terminal ileum demonstrated no pathological alterations.

Test 2 weeks Before Admission

OnAdmission

Week1

Week2

Week3

Week4

AfterERCP

OnDischarge

1 monthlater

Total bilirubin (mg/dL) 14.8 34.75 24.1 24.5 22.7 18.8 11.6 5.2 2.1Direct bilirubin (mg/dL) 13.2 29.35 22.5 23.8 20.1 16.3 9.8 4.3 2Total Protein (gm/dL) -- 6.7 5.8 -- 5.6 5.5 5.9 6 6.1Albumin (gm/dL) -- 3.8 3.1 3.5 3 2.9 2.9 3.1 3.9AST (IU/dL) 169 208 178 204 176 171 157 76 44ALT (IU/dL) 499 156 109 187 105 90 101 82 43ALP (IU/dL) -- 156 137 161 149 123 152 133 122GGT (IU/dL) 122 47 39 37 43 38 64 64 63Urea (mg/dL) -- 16 14 -- -- -- -- 15 18Creatinine (mg/dL) 1.2 0.6 0.9 -- -- -- 0.7 0.5 0.7GGT: Gamma-Glutamyl Transpeptidase; ALP: Alkaline Phosphatase; ALT: Alanine Aminotransferase; AST: Aspartate Aminotransferase.

Table 1: Laboratory data.

Figure 1: Serum total and direct billirubin during hospitalizion the illness period.

0

100

200

300

400

500

600

1 2 3 4 5 6 7 8

AST

ALT

Figure 2: AST and ALT during hospitalization.

Figure 3: Liver biopsy showing fibrous expansion of portal tract (left side) exhibiting bile ductular reaction (black arrow) with accompanying portal edema and mild mixed inflammation. The hepatic parenchyma sowed intracanalicular cholestasis with cholestatic rosettes (red arrows), intracytoplasmic cholestasis, feathery degeneration and inflammation, along with giant cell transformation. (H and E, x200).

Figure 4: Liver biopsy showing moderately disturbed lobular architecture by fibrous expansion of portal tract (left side) exhibiting moderate bile ductular proliferation (red arrow) with accompanying portal tract oedema moderate/marked mixed inflammation (lymphoplasmacytic and neutrophils) exceeding the limiting plates. The parenchyma showed intracytoplasmic cholestasis, feathery degeneration and parenchymal inflammation. (H and E, x200).

Citation: El-Sabaawy MM, Abdel-Sameea E, Abdallah AR, El-Refaey A, Soltan M, et al. (2017) IgG4 Sclerosing Cholangitis and Post Infantile Giant Cell Hepatitis: A Case Report of an Extraordinary Co-presentation. J Mol Biomark Diagn 8: 348. doi: 10.4172/2155-9929.1000348

Page 3 of 5

Volume 8 • Issue 4 • 1000348J Mol Biomark Diagn, an open access journalISSN:2155-9929

The patient improved further in both general condition and laboratory investigations. Endosonography (EUS) showed no abnormality, and biopsies taken from the distal common duct showed no evidence of malignancy.

One year later the patient had normal liver tests, and liver stiffness measurement by Fibroscan showed the presence of cirrhosis (stiffness was 11 kPa). Repeat examination of terminal ileum and colonic tissues revealed absence of features of inflammatory bowel disease.

DiscussionPSC is a chronic cholestatic disorder with significantly increased

risk of cholangiocarcinoma (CCA) that demands constant vigilance [11]. The heterogeneous presentation characterizing PSC involves at least four variants: “Classical” PSC (involving the intrahepatic or extrahepatic biliary tree or both), small-duct PSC, PSC/autoimmune hepatitis (AIH) overlap syndrome, and the IgG4 associated cholangitis (IgG4-SC) or immune associated cholangiopathy (IAC) [12].

The diagnosis of IAC can be challenging because of paucity of related scientific work and lack of high level evidence of management [4].

IAC is a distinguished variant of PSC, characterized by elevated serum IgG4 and infiltration of IgG4-positive plasma cells in bile ducts and liver tissue, with notable association with autoimmune pancreatitis (AIP) [13].

The validity of serum IgG 4 as a diagnostic marker for IgG4-SC (IAC) has been repeatedly questioned. Many studies have shown associations between elevated serum IgG4 and non-IgG4 disorders as cholangiocarcinoma, pancreatic carcinoma, inflammatory bowel disease and systemic lupus erythematosus (SLE). In addition, IgG4 levels have been found within the normal range in up to 40% of patients having typical histopathological diagnosis of IgG4-SC, and one half of those with elevated IgG4 do not meet IAC diagnostic criteria [14].

In this case, we did not test for serum levels of IgG4, and resorted to immune-staining of liver tissue, as this is the hallmark for diagnosing IgG4-SC. Histopathological features and, more definitely, the positive IgG4 immunostaining were present in the liver tissue, which were crucial in diagnosing this case as IgG4-SC (IAC). Infiltration of IgG4 positive plasma cells and the presence of periportal fibro-inflammatory nodules were evident in the present case, and were previously reported as features suggestive of IgG4-RD-SC. Ductopenia and periductal concentric fibrosis, typical of the prototype PSC, were absent in this case [15].

Additional sensitive but less specific markers of IAC include hyper gamma-globulinemia (observed in 50% of patients), antinuclear antibodies (40–50%), rheumatoid factor (20%), and eosinophilia (15–25%) [16]. Autoantibody against SS-A (Ro) or SS-B (La), antimitochondrial antibody, and antineutrophilic cytoplasmic antibody (ANCA) are all exceptional (<5%) in IAC [17]. Therefore, the positive P-ANCA reported in this case pointing to PSC does not exclude the possible presence of IgG4-SC.

Comprehensive histopathological analysis showed that 23% of liver explants of PSC patients had increased immunohischemical staining of IgG4 periductal plasma cells, with corresponding histopathological features of classic PSC. Some authors have stated that combined histological findings and positive immunostaining are not enough to diagnose IgG4-SC [18]. Therefore, other diagnostic tools as serum markers and radiologic studies are essential, not only for IAC diagnosis, but also for ruling out the possibility of cholangiocarcinoma, especially in patients’ presenting with hilar cholangiopathy [19].

Figure 5: Parenchymal intracytoplasmic and intracanalicular cholestasis together with feathery degeneration and mixed inflammation along with evident giant cell transformation (Hand E x400).

Figure 6: Positive cytoplasmic staining of Ig4 in plasma cellular infiltrate in portal tract (IPS, x400).

Figure 7: Positive cytoplasmic staining of Ig4 in plasma cellular infiltrate within the parenchyma (IPS, x400).

Figure 8: (a) ERCP showing a short segment of thickened CBD, with dilated common hepatic duct and (b) intrahepatic biliary radicles.

Citation: El-Sabaawy MM, Abdel-Sameea E, Abdallah AR, El-Refaey A, Soltan M, et al. (2017) IgG4 Sclerosing Cholangitis and Post Infantile Giant Cell Hepatitis: A Case Report of an Extraordinary Co-presentation. J Mol Biomark Diagn 8: 348. doi: 10.4172/2155-9929.1000348

Page 4 of 5

Volume 8 • Issue 4 • 1000348J Mol Biomark Diagn, an open access journalISSN:2155-9929

ERCP had displayed superior results over the less invasive MRCP in recognition of early or single large duct PSC. The MRCP views in these conditions might not be the most advantageous [1] which might explain normal MRCP in this case.

Valchou et al., in their study of IAC cases, found 43% of cases presenting with isolated extrahepatic bile duct involvement, and only 5% with intrahepatic bile duct involvement, while the copresentation was evident in 52%, and in 20% only the intra-pancreatic portion of the common bile duct was involved [20]. Isolated strictures of the distal common bile duct also are common [21]. Placement of a temporary endoscopic biliary stent or percutaneous biliary drainage was performed in 26 patients (59%) to relieve jaundice [20]. According to the findings of the ERCP; the present case belongs to the group of isolated CBD stricture and placement of a plastic stent was successfully undertaken.

Type 1 auto-immune pancreatitis (AIP) is part of the IgG4-RD that often affects multiple organs including the pancreas, bile ducts, salivary glands, kidneys and lymph nodes [22]. The isolated IgG4-SC without the mutually described AIP has been reported in a small number of cases. It has been reported that AIP is absent in 10% of IAC cases [23,24]. A recent report described a series of six Japanese cases of IAC without clinically manifest AIP [25] and the current case is similar to the cases in this report.

Patients with IgG4-RD respond beneficially to corticosteroid therapy, especially when given at early stages. A good initial therapeutic response to corticosteroids is characteristic, particularly in those whose excessive tissue fibrosis has not yet supervened [20]. Without treatment, IgG4-SC may be self-limited, or it may asymptomatically progress and lead to biliary cirrhosis [20].

Despite the proposed mutual autoimmune background for both ailments, the association between AIC and inflammatory bowel disease is still blurred, with a few scattered undetermined studies. Ravi et al. had detected inflammatory bowel disease in 6% of patients with proved autoimmune pancreatitis, while in Zamboni et al. the incidence heightened to 17% [26,27].

PIGCH is rare histopathological description that has been reported basically in connection to serious medical disorders [10]. Whereas its pathogenesis remains unsettled; amalgamated mononuclear hepatocytes versus nuclear proliferation without cell division have been proposed as the pathogenic basis [28].

In most of the time PIGCH presents as self-limited acute hepatitis but it can be chronic or progressively fulminant [29]. However, the background etiology is the main determinant of the outcome after one or repeated attacks of PIGCH.

This case presented with prolonged cholestastasis and acute hepatitis, along with combined histological features of both PIGCH and IAC. In absence of PIGCH related etiologies previously mentioned in the literature, the concurrent occurrence of GCH in this case could be attributed to the existence of IAC. Apart from this case, only a few cases of PIGCH presenting simultaneously with classic type PSC/autoimmune hepatitis overlap cases have been reported [9,30,31].

ConclusionThis case presented with both IgG4-SC and biopsy proven PIGCH,

and had a favourable outcome with biliary drainage and immuno-suppression therapy.

References

1. Horsley-Silva JL, Carey EJ, Lindor KD (2016) Advances in primary sclerosing cholangitis. Lancet Gastroenterol Hepatol 1: 68-77.

2. Sarkar S, Bowlus L (2016) Primary sclerosing cholangitis multiple phenotypes, multiple approaches. Clin Liver Dis 20: 67-77.

3. Nakazawa T, Naitoh I, Hayashi K, Okumura F, Miyabe K, et al. (2012) Diagnostic criteria for IgG4-related sclerosing cholangitis based on cholangiographic classification. J Gastroenterol 47: 79-87.

4. Zen Y, Harada K, Sasaki M, Sato Y, Tsuneyama K, et al. (2004) IgG4-related sclerosing cholangitis with and without inflammatory pseudotumor, and sclerosing pancreatitis-associated sclerosing cholangitis: Do they belong to a spectrum of sclerosing pancreatitis? Am J Surg Pathol 28: 1193-1203.

5. Björnsson E, Chari S, Silveira M, Gossard A, Takahashi N, et al. (2011) Primary sclerosing cholangitis associated with elevated immunoglobulin G4: clinical characteristics and response to therapy. Am J Ther 18: 198-205.

6. Kahn A, Yadav A, Edwyn M Harrison (2015) IgG4-seronegative autoimmune pancreatitis and sclerosing cholangitis. Case Reports in Gastrointestinal Medicine ID: 591360.

7. Bianchi L, Terracciano LM (1994) Giant cell hepatitis in adults. Praxis 83: 1237-1241.

8. Bihari C, Rastogi A, Sarin SK (2013) Postinfantile giant cell hepatitis: An etiological and prognostic perspective. Hepat Res Treat 601283: 601290.

9. Protzer U, Dienes HP, Bianchi L, Lohse AW, Helmreich-Becker I, et al. (1996) Post-infantile giant cell hepatitis in patients with primary sclerosing cholangitis and autoimmune hepatitis. Liver 16: 274-282.

10. Johnson SJ, Mathew J, MacSween RN, Bennett MK, Burt AD (1994) Post-infantile giant cell hepatitis: histological and immunohistochemical study. J Clin Pathol 47: 1022-1027.

11. Razumilava N, Cancer Gores GJ, Lindor KD (2011) Cancer surveillance in patients with primary sclerosing cholangitis. Hepatology 54: 1842-1852.

12. Floreani A (2011) Clinical variants of primary sclerosing cholangitis: When does liver biopsy make the diagnosis? Liver biopsy in modern medicine, Dr. Yoshiaki Mizuguchi (Ed.) ISBN: 978-953-307-883-0.

13. Ghazale A, Chari ST, Zhag L, Smyrk TC, Takahashi N, et al. (2008) Immunoglobulin G4-associated cholangitis: clinical profile and response to therapy. Gastroenterology 134: 706-715.

14. Yamamoto M, Shimizu Y, Yajima H, Tabeya T, Suzuki C, et al. (2016) Validation of the comprehensive diagnostic criteria for IgG4-related disease in a SMART registry. Mod Rheumatol 26: 310-312.

15. Deshpande V, Sainani NI, Chung RT, Pratt DS, Mentha G, et al. (2009) IgG4-associated cholangitis: A comparative histological and immunophenotypic study with primary sclerosing cholangitis on liver biopsy material. Mod Pathol 22: 1287-1295.

16. Okazaki K, chida K, Fukui T (2008) Recent advances in autoimmune pancreatitis: concept, diagnosis, and pathogenesis. J Gastroenterol 43: 409-418.

17. Park D, Kim M, Chari S (2009) Recent advances in autoimmune pancreatitis. Gut 58: 1680-1689.

18. Zhang L, Lewis JT, Abraham SC, Smyrk TC, Leung S, et al. (2010) IgG4+ plasma cell infiltrates in liver explants with primary sclerosing cholangitis. Am J Surg Pathol 34: 88-94.

19. Nakazawa T, Ando T, Hayashi K, Naitoh I, Ohara H, et al. (2010) Diagnostic procedures for IgG4-related sclerosing cholangitis. World J Gastroenterol 18: 127-136.

20. Vlachos P, Khalili K, Jang H, MD, Fischer S, Hirschfield G, et al. (2011) igg4-related sclerosing disease: autoimmune Pancreatitis and Extrapancreatic Manifestations. RadioGraphics 31: 1379-1402.

21. Nakazawa T, Ohara H, Sano H, Aoki S, Kobayashi S, et al. (2004) Cholangiography can discriminate sclerosing cholangitis with autoimmune pancreatitis from primary sclerosing cholangitis. Gastrointest Endosc 60: 937-944.

22. Huggett MT, Culver EL, Kumar M, Hurst JM, Rodriguez-Justo M, et al. (2014) Type 1 autoimmune pancreatitis and IgG4-related sclerosing cholangitis is

Citation: El-Sabaawy MM, Abdel-Sameea E, Abdallah AR, El-Refaey A, Soltan M, et al. (2017) IgG4 Sclerosing Cholangitis and Post Infantile Giant Cell Hepatitis: A Case Report of an Extraordinary Co-presentation. J Mol Biomark Diagn 8: 348. doi: 10.4172/2155-9929.1000348

Page 5 of 5

Volume 8 • Issue 4 • 1000348J Mol Biomark Diagn, an open access journalISSN:2155-9929

associated with extrapancreatic organ failure, malignancy, and mortality in a prospective UK cohort. Am J Gastroenterol 109: 1675-1683.

23. Hamano H, Kawa S, Uehara T, Ochi Y, Takayama M, et al. (2005)Immunoglobulin G4-related lymphoplasmacytic sclerosing cholangitis thatmimics infiltrating hilar cholangiocarcinoma: Part of a spectrum of autoimmune pancreatitis? Gastrointest Endosc 62: 152-157.

24. Takikawa H (2007) Characteristics of primary sclerosing cholangitis in Japan.Hepatol Res 37: S470-473.

25. Matsubayashi H, Uesaka K, Sugiura T, Ohgi K, Sasaki K, et al. (2014) IgG4-related sclerosing cholangitis without obvious pancreatic lesion: Difficulty in differential diagnosis. J Dig Dis 15: 394-403.

26. Ravi K, Chari ST, Vege SS, Sandborn WJ, Smyrk TC (2009) Inflammatory bowel disease in the setting of autoimmune pancreatitis. Inflamm Bowel Dis 15: 1326-1330.

27. Zamboni G, Lüttges J, Capelli P, Frulloni L, Cavallini G, et al. (2004)Histopathological features of diagnostic and clinical relevance in autoimmunepancreatitis: a study on 53 resection specimens and 9 biopsy specimens.Virchows Arch 445: 552-563.

28. Johnson J, Mathew J, MacSween R, Bennett M, Burt A (1994) Post-infantilegiant cell hepatitis: histological and immunohistochemical study. J Clin Pathol47: 1022-1027.

29. Kinra P, John BM (2007) Hepatitis-A induced non-infantile giant cell hepatitis.Med J Armed Forces India 63: 182-183.

30. Ben-Ari Z, Broida E, Monselise Y, Kazatsker A, Baruch J, et al. (2000) Syncytial giant-cell hepatitis due to autoimmune hepatitis type II (LKM1+) presenting assub-fulminant hepatitis. Am J Gastroenterol 95: 799-801.

31. Thijs JC, Bosma A, Henzen-Logmans SC, Meuwissen SG (1985) Post-infantile giant cell hepatitis in a patient with multiple autoimmune features. Am JGastroenterol 80: 4: 294-297.